Title: First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma
Abstract: Sorafenib is the only agent approved for first-line treatment of patients with advanced hepatocellular cancer (HCC). Regorafenib and nivolumab are the
Publication Year: 2018
Publication Date: 2018-02-22
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot